bioavailable EP300/CBP HAT inhibitor

brain penetrant, orally efficacious in xeno.

from HTS and SBDD

ACS Med. Chem. Lett., Apr. 27, 2020

Constellation Pharma., Cambridge, MA

CPI-1612 is a pretty efficient-looking EP300/CBP histone acetyltransferase (HAT) inhibitor tool compound with demonstrated activity in a xenograft model and good higher species PK. While epigenetics targets like HATs have…

 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.